Claes Buxfeldt, former global price and reimbursement director at AstraZeneca, has joined the NDA Advisory Board. During the last 18 years Claes has worked on a variety of disease areas, supporting more than 30 molecules/brands in a global position. He has represented the payer voice in the development programs including the development of payer evidence strategies, pricing and market access strategy, economic models, PROs, RWE and clinical program input. He joined AstraZeneca in 2009 as value demonstration leader in global health economics & outcomes research.
